MedTrace Logo

A Longitudinal Study of Severe and Enduring Eating Disorders

NCT06752304 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2024-12-31

No results posted yet for this study

Summary

The goal of this observational longitudinal study is to investigate characteristics and factors associated with the development of Severe and Enduring Eating Disorders (SEED). In this project, the researchers will follow two prospective cohorts of patients with eating disorders (ED), one adolescent (ages 14-17) and one adult (ages 18+), in terms of change in and impact of clinical, psychological, and biological risk factors.

Data will be collected at baseline, after treatment, two years after baseline, and thereafter five, 10 and 20 years after baseline. Participants will be asked to undergo a physical examination, leave blood samples, be interviewed, and fill in questionnaires. If the participants are minors, their care takers will also fill in the questionnaires.

The study aims to explore how clinical, psychological, and biological risk factors-including comorbidity, personality characteristics, difficulties with emotion regulation (ER), cognitive inflexibility, loneliness, severe ED symptoms, and inflammatory activation-contribute to a chronic course of the disorder.

Conditions

  • Eating Disorders
  • Anorexia Nervosa
  • Bulimia Nervosa
  • Binge Eating Disorder
  • Other Specified Feeding or Eating Disorder

Sponsors & Collaborators

  • Forte

    collaborator INDUSTRY

  • The Söderström König Foundation

    collaborator UNKNOWN

  • Fonden för psykisk hälsa

    collaborator UNKNOWN

  • Uppsala University Hospital

    lead OTHER

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2029-12-31
Completion
2048-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06752304 on ClinicalTrials.gov